Cancer prevention and therapy by inhibiting soluble tumor necrosis factor
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsNikola L. Vujanovic, Lazar Vujanovic
Life of this patent
Estimating the term…
Abstract
Methods are disclosed for inhibiting the development of a tumor in a subject. The methods include administering to a subject a therapeutically effective amount of a dominant negative tumor necrosis factor (DN-TNF)-α protein and/or a nucleic acid encoding the DN-TNF-α protein. The DN-TNF-α protein and/or a nucleic acid encoding the DN-TNF-α protein can be administered alone or in combination with other agents.
Claims17
A method for expanding helper T cells, cytotoxic T cells, or both in a subject with cancer, comprising administering to the subject a therapeutically effective amount of a dominant negative tumor necrosis factor (DN-TNF)-α protein and/or a nucleic acid encoding the DN-TNF-α protein, thereby increasing expanding antitumor helper T cells and/or cytotoxic T cells in the subject, and treating the cancer.
A method for treating a subject suffering from a cancer characterized by elevated myeloid derived suppressor cells (MDSCs), the method comprising:
- administering to the subject a therapeutically effective amount of a dominant negative tumor necrosis factor (DN-TNF)-α protein and/or a nucleic acid encoding the DN-TNF-α protein, thereby inhibiting the number and/or function of said MDSCs, whereby the subject is treated.
Dependencies are inferred from the claim text.